Sorrento Up on Request for Emergency Authorization for Covid Test
Sorrento Therapeutics jumped after the biopharma said it applied for FDA emergency-use authorization for its covid-19 test.
Author:
Sorrento Therapeutics (
SRNE) - Get Report shares jumped after the biopharma said it had applied to the Food and Drug Administration for emergency-use authorization for its covid-19 test.
The stock recently traded at $8.80, up 22%. It had well more than doubled year to date amid optimism about its covid efforts.
The test is called Covi-Stix. “In testing conducted to date, Covi-Stix has provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load,” Sorrento said in a statement.
IU Lands $37M Grant to Develop COVID Treatment insideindianabusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insideindianabusiness.com Daily Mail and Mail on Sunday newspapers.
Date Time
$37.6M grant awarded to develop innovative COVID-19 treatment
While the world is focused on the promise of the COVID-19 vaccines now being released, researchers continue to look for new and innovative ways to fight the pandemic. Indiana University is part of a consortium including AstraZeneca, the Wistar Institute, Inovio and the University of Pennsylvania that just received a $37.6 million grant to develop and study DNA-encoded monoclonal antibodies as an additional way to fight SARS-CoV-2, the virus that causes COVID-19.
The grant, awarded from the Defense Advanced Research Projects Agency and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, will enable IU and its consortium partners to take its DNA-encoded monoclonal antibodies from the design stage into human phase II clinical trials in the next two years. The technology works by providing the genetic information the body needs to produce its own antibodies against a
Share this article
Share this article
PALM BEACH, Fla., Dec. 21, 2020 /PRNewswire/ Since the global outbreak that triggered the pandemic, scientists around the world have been working on potential treatments and vaccines for the new coronavirus disease known as COVID-19… and they have been making progress at a rapid pace, perhaps the fastest in history. Several companies are working on antiviral drugs, some of which are already in use against other illnesses, to treat people who have COVID-19, which could provide the fastest track of all. Other companies are working on vaccines that could be used as a preventive measure against the disease. Last week, the FDA granted emergency use authorization for a COVID-19 vaccine created by Pfizer-BioNTech. An article in Medical News today added: The United States is the latest country to join Canada and the United Kingdom in approving a COVID-19 vaccine. Creating a vaccine in under 1 year is no small feat. While the coronavirus pa
genetic variants that influence the amount or function of human
“helper proteins” that support or facilitate SARS-CoV-2. The gene variants reveal potential target structures for new drugs. The researchers have now published their results in
Nature Communications. The team examined 179 proteins known to be involved in SARS-CoV-2 infection for their naturally occurring variants. They discovered 38 targets for existing drugs as well as evidence that certain proteins that interact with the virus influence the immune system. DOI: 10.1038/s41467-020-19996-z
In
all-cause excess mortality and COVID-19–related mortality during the early pandemic period among adults aged
25 to 44 years. Because unintentional drug overdoses are the usual leading cause of death in this demographic, COVID-19 deaths were compared with unintentional opioid deaths. From March 1, 2020, to July 31, 2020, a total of 76,088 all-cause deaths occurred among US adults aged 25 to 44 years, which was 11,899 mo